The Mark Foundation for Cancer Research today announced four recipients of the 2026 Drug Discovery Awards, a program designed to bridge the gap between academic discovery and clinical application.
Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results